Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709192 | 0.89 | KDM4E (0.33) | TSHRKDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5884001 | 0.77 | APLNR (0.47) | TSHRTRPV1HIF1A | |
| SCHEMBL4087934 | 0.74 | NAAA (0.40) | TSHRHIF1A | |
| SCHEMBL11926437 | 0.73 | KDM4E (0.35) | TSHRHIF1AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL5253771 | 0.72 | TAAR1 (0.46) | TSHRTRPV1HIF1AKDM4EL3MBTL1 | |
| SCHEMBL24259322 | 0.72 | ALDH1A1 (0.34) | TSHRHIF1AKDM4EALDH1A1 | |
| SCHEMBL12523721 | 0.71 | KDM4E (0.37) | TSHRHIF1AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL830410 | 0.70 | KDM4E (0.38) | KDM4EL3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL27357766 | 0.70 | HRH3 (0.33) | KDM4EL3MBTL1ALDH1A1HPGDCYP1A2 | |
| SCHEMBL21339914 | 0.69 | SMN1; SMN2 (0.41) | TSHRHIF1AKDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| CN-1247547-C | Piperidine and piperazine substituted N-hydroxyformamides as inhibitors of metalloproteinases | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| CN-1418197-A | Piperidine and piperazine substituted N-hydroxycarboxamides as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | CN | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | TSHR 4597/4885TRPV1 2883/4885HIF1A 906/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | TSHR 4551/4885TRPV1 4142/4885HIF1A 1188/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | TSHR 4597/4885TRPV1 2883/4885HIF1A 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.